Wipfli Financial Advisors’s Anavex Life Sciences AVXL Stock Holding History

Wipfli Financial Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+137	New	+$1.45K	﹤0.01%	2371

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wipfli Financial Advisors's AVXL Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Anavex Life Sciences (AVXL) in Q3 2022: 137 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2371 among its holdings.

147 funds tracked by Wall St. Rank hold AVXL as of Q3 2022.

Wipfli Financial Advisors held 137 shares of Anavex Life Sciences worth $1K as of Q3 2022.
Anavex Life Sciences was a new Wipfli Financial Advisors position in Q3 2022.
Anavex Life Sciences made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2371 holding.
147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.